Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311320 | 0.83 | ACHE (0.37) | ACHECA9CYP3A4MAPT | |
| SCHEMBL3396123 | 0.77 | — | — | |
| SCHEMBL27661643 | 0.77 | HTR2A (0.34) | — | |
| SCHEMBL27814463 | 0.77 | HTR2A (0.34) | — | |
| SCHEMBL2154014 | 0.74 | ACHE (0.41) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL745028 | 0.74 | ACHE (0.36) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL312248 | 0.73 | ACHE (0.34) | ACHECA9CYP3A4MAPTMAOA | |
| SCHEMBL311915 | 0.73 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL313310 | 0.73 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL1466344 | 0.73 | MAPT (0.43) | ACHECA9CYP3A4MAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505933-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | claimed |
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101906106-A | New heterogeneous ring compound as the HSP90-inhibitor | CONFORMA THERAPEUTICS CORP | 2010-12-08 | — | — | CN | disclosed |
| CN-1882589-B | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP | 2010-06-09 | — | — | CN | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-2012791-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| US-7138402-B2 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-7129244-B2 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4880/4885CA9 4805/4885CYP3A4 4204/4885 |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4873/4885CA9 4825/4885CYP3A4 3491/4885 |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | HSP90B1, HSP90AB2P, HSP90AB1 | ACHE 4813/4885CA9 4777/4885CYP3A4 4723/4885 |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4879/4885CA9 4851/4885CYP3A4 4441/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4879/4885CA9 4826/4885CYP3A4 4260/4885 |
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4873/4885CA9 4783/4885CYP3A4 3640/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | ACHE 4876/4885CA9 4470/4885CYP3A4 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.